Table 1.
Baseline characteristics and follow-up data
| Value | |
|---|---|
| Age (years) | 30 (8 to 82) |
| Women (%) | 58 |
| BMI | 22 ± 3 |
| MAP (mmHg) | 92 ± 15 |
| eGFR (ml/min per 1.73 m2) | 82 ± 35 |
| CKD stages 1/2/3/4/5 (%) | 37/37/21/3/1 |
| UP-UCR (g/gcr) | 0.85 (0 to 17) |
| ACEI/ARB (%) | 3 |
| Follow-up data | |
| follow-up (months) | 62 (6a to 281) |
| steroid (%) | 32 |
| ACEI/ARB (%) | 37 |
| ESRF (%) | 12 |
BMI, body mass index; MAP, mean arterial pressure; eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease; UP-UCR, urinary protein creatinine excretion ratio; ACEI, angiotensin converting enzume inhibitor; ARB, angiotensin receptor blocker; ESRF, end-stage renal failure.
a
Eight patients developed ESRF within 12 months.